Mulholland 1997.

Methods	Allocation: randomised, computer generated numbers. Blindness: double, identical placebo capsules. Duration: 8 weeks.
Participants	Diagnosis: schizophrenia (DSM‐III‐R), depression (>= 3 on BPRS depression and >= 15 on BDI). N=26. Sex: female 10, male 16. Age: mean 38 years. History: duration ill ˜ 15 years. Setting: out‐patients. Phase: stable, no admission to hospital in previous 6 months. Medication History: people with significant EPS excluded. All on neuroleptic medication. 16 of the 26 were on anticholinergics.
Interventions	1. Sertraline: dose 50 mg/day 4 weeks, 100 mg/day next 4 weeks if tolerated. N=13. 2. Placebo. N=13. Both groups: neuroleptic and anticholinergic.
Outcomes	Mental State: HAM(D), BPRS. Leaving the study early. Clinical recovery: CGI minimal or better improvement. Unable to use ‐ Mental state: BDI (HAM(D) used in preference).
Notes	ITT analysis performed. Unpublished results provided by authors.
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment (selection bias)	Low risk	A ‐ Adequate